logo

For the Inventor, By the Inventor

Ibaraki, Japan

Yoshimori Sakuma

This inventor holds 7 USPTO granted patents. Top assignee: Eisai Company, Limited. Active years: 1993-1996.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yoshimori Sakuma. Retrieved from https://idiyas.com/inventor/yoshimori-sakuma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 100.0

Average Co-Inventor Count = 20.0

ph-index = 2

Forward Citations = 21(Granted Patents)


Company Filing History:

goldMedal7 out of 677 
 
Eisai Company, Limited
 patents

Years Active: 1993-1996

Loading Chart...
7 patents (USPTO):Explore Patents
1. 5482937 - 1,4-diazepine derivative and its pharmaceutical use (1996-01-09),
2. 5468740 - 1,4-diazepine derivative and its pharmaceutical use (1995-11-21),
3. 5438045 - 1,4-diazepine derivative and its pharmaceutical use (1995-08-01),
4. 5409909 - 1,4-diazepine derivative and its pharmaceutical use (1995-04-25),
5. 5382579 - Triazolo-1,4-diazepine derivatives and their use in pharmaceuticals (1995-01-17),
6. 5304553 - 1,4-diazepine derivative and its pharmaceutical use (1994-04-19),
7. 5221671 - Triazolo-1,4-diazepine derivatives and their use in pharmaceuticals (1993-06-22),

Title: Innovations of Yoshimori Sakuma

Introduction

Yoshimori Sakuma is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the pharmaceutical field, particularly through his innovative work on 1,4-diazepine derivatives. With a total of seven patents to his name, Sakuma's inventions are aimed at addressing various medical challenges, especially allergic diseases.

Latest Patents

Sakuma's latest patents include a triazolo-1,4-diazepine compound that is useful in treating allergic diseases. The compound is described by a specific formula where R¹ and R² can be hydrogen or an alkyl, R³ is hydrogen or a halogen, R⁴ is hydrogen or an alkyl, X can be --OCO--, and Y can be a cycloalkyl, a cycloalkylalkyl, an alkynyl, or others. Another patent focuses on a similar triazolo-1,4-diazepine compound, which also serves a pharmacological purpose in treating allergic conditions.

Career Highlights

Sakuma is currently employed at Eisai Company, Limited, where he continues to develop innovative pharmaceutical solutions. His work has been instrumental in advancing the understanding and treatment of allergic diseases through his patented compounds.

Collaborations

Sakuma has collaborated with notable colleagues such as Kazuo Okano and Shuhei Miyazawa, contributing to a dynamic research environment that fosters innovation.

Conclusion

Yoshimori Sakuma's contributions to the field of pharmaceuticals through his patents on 1,4-diazepine derivatives highlight his role as a significant inventor. His work not only showcases his innovative spirit but also aims to improve the quality of life for those suffering from allergic diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…